BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O'Donnell K, Marzi A. The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms. Expert Rev Vaccines 2020;19:267-77. [PMID: 32129120 DOI: 10.1080/14760584.2020.1738225] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Pinski AN, Messaoudi I. Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity. Curr Opin Virol 2021;51:179-89. [PMID: 34749265 DOI: 10.1016/j.coviro.2021.10.007] [Reference Citation Analysis]
2 Li M, Liang Z, Chen C, Yu G, Yao Z, Guo Y, Zhang L, Bao H, Fu D, Yang X, Wang H, Xue C, Sun B. Virus-Like Particle-Templated Silica-Adjuvanted Nanovaccines with Enhanced Humoral and Cellular Immunity. ACS Nano 2022. [PMID: 35763693 DOI: 10.1021/acsnano.2c01283] [Reference Citation Analysis]
3 Mara K, Dai M, Brice AM, Alexander MR, Tribolet L, Layton DS, Bean AGD. Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production. Vaccines (Basel) 2021;9:59. [PMID: 33477334 DOI: 10.3390/vaccines9010059] [Reference Citation Analysis]
4 Anderson MS, Niemuth NA, Sabourin CL, Badorrek CS, Bounds CE, Rudge TL Jr. Interlaboratory comparison for the Filovirus Animal Nonclinical Group (FANG) anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay. PLoS One 2020;15:e0238196. [PMID: 32841291 DOI: 10.1371/journal.pone.0238196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ, Ahmadian G. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology 2021;19:59. [PMID: 33632278 DOI: 10.1186/s12951-021-00806-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
6 Nielsen CM, Ogbe A, Pedroza-Pacheco I, Doeleman SE, Chen Y, Silk SE, Barrett JR, Elias SC, Miura K, Diouf A, Bardelli M, Dabbs RA, Barfod L, Long CA, Haynes BF, Payne RO, Minassian AM, Bradley T, Draper SJ, Borrow P. Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors. Cell Rep Med 2021;2:100207. [PMID: 33763653 DOI: 10.1016/j.xcrm.2021.100207] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
7 Söderlund-Venermo M, Varma A, Guo D, Gladue DP, Poole E, Pujol FH, Pappu H, Romalde JL, Kramer L, Baz M, Venter M, Moore MD, Nevels MM, Ezzikouri S, Vakharia VN, Wilson WC, Malik YS, Shi Z, Abdel-Moneim AS. World Society for Virology first international conference: Tackling global virus epidemics. Virology 2022;566:114-21. [PMID: 34902730 DOI: 10.1016/j.virol.2021.11.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sharma AR, Lee YH, Nath S, Lee SS. Recent developments and strategies of Ebola virus vaccines. Curr Opin Pharmacol 2021;60:46-53. [PMID: 34329960 DOI: 10.1016/j.coph.2021.06.008] [Reference Citation Analysis]